07:56 AM EST, 02/25/2025 (MT Newswires) -- Tarsus Pharmaceuticals ( TARS ) narrowed its Q4 loss to $0.60 per diluted share from $1.31 per share a year earlier.

Analysts polled by FactSet expected a loss of $0.74 per share.

Revenue for the quarter ended Dec. 31 was $66.4 million compared with $13.1 million a year earlier.

Analysts surveyed by FactSet expected $58.8 million.

Tarsus shares were more than 9% higher in premarket trading.